AngioDynamics, Inc. (NASDAQ: ANGO) is a leading provider of innovative, minimally invasive medical devices used by healthcare professionals for vascular access, peripheral vascular disease, oncology, and surgery. The company's diverse product lines are designed to improve patient outcomes and procedural efficiency. AngioDynamics is committed to advancing patient care through a portfolio that includes ablation systems, fluid management systems, vascular access products, and solutions for thrombus management and venous insufficiency. With a focus on research and development, AngioDynamics strives to deliver cutting-edge technologies that address critical medical needs and enhance the quality of life for patients worldwide.
Serves as the global corporate center, housing executive leadership, administrative, research and development, and strategic operations functions.
Modern corporate office facility designed to foster collaboration and innovation. May include R&D labs and training facilities for medical professionals.
A professional and collaborative environment focused on innovation in medical technology, with an emphasis on improving patient outcomes. Employees are often mission-driven, contributing to life-saving and life-enhancing products.
The headquarters is central to AngioDynamics' global strategy, product development pipeline, and corporate governance. Its location in New York's 'Tech Valley' provides access to a skilled workforce and research institutions.
AngioDynamics supports global healthcare markets through direct sales operations, a network of distributors, and strategically located offices and manufacturing facilities. Key functions supported globally include sales and marketing, customer service, clinical support, product distribution, and regulatory affairs, enabling the company to serve patients and healthcare providers in numerous countries across North America, Europe, Asia, and other international markets.
14 Plaza Drive
Latham
New York
United States
Address: 603 Queensbury Ave, Queensbury, NY 12804
Supports the company's manufacturing needs, leveraging the skilled labor and infrastructure in upstate New York, an area with a history in manufacturing and technology.
Address: AngioDynamics Netherlands B.V., Piet Heinkade 93 B, 1019 GM Amsterdam, The Netherlands
Facilitates AngioDynamics' commercial operations and expansion in the European market, providing a strategic base for engaging with healthcare providers and distributors across the region.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AngioDynamics' leadership includes:
AngioDynamics has been backed by several prominent investors over the years, including:
AngioDynamics has made strategic appointments and seen some changes in its executive team over the past 12 months, notably strengthening its U.S. commercial leadership and recognizing internal talent through promotions.
Discover the tools AngioDynamics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
AngioDynamics primarily utilizes the email format combining the first initial of an employee's name followed by their last name. For example, an employee named Jane Doe would likely have an email address such as jdoe@angiodynamics.com. While other formats might exist within the organization, this is the most common pattern.
[first_initial][last]@angiodynamics.com
Format
jdoe@angiodynamics.com
Example
85%
Success rate
AngioDynamics Investor Relations / Business Wire • March 28, 2024
AngioDynamics announced its financial results for the third quarter of fiscal year 2024, reporting net sales of $80.6 million. The company highlighted progress in its MedTech platforms, including Auryon and AlphaVac, and reaffirmed its full-year revenue and adjusted earnings per share guidance....more
AngioDynamics Investor Relations / Business Wire • February 13, 2024
AngioDynamics announced the appointment of Scott Centea as Senior Vice President, U.S. Commercial Sales, effective February 12, 2024. Mr. Centea brings over two decades of experience in the medical device industry to lead the company's U.S. commercial organization....more
AngioDynamics Investor Relations / Business Wire • January 8, 2024
AngioDynamics reported financial results for its second quarter of fiscal year 2024, with net sales of $81.2 million. The company noted growth in its MedTech product categories, Auryon and AlphaVac, and updated its financial guidance for the fiscal year....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AngioDynamics, are just a search away.